Rondaxe and TD2 form strategic drug development alliance
TGen Drug Development (TD2) and Rondaxe Enterprises announced a strategic alliance that will help emerging companies speed new high-quality treatments to cancer patients. Rondaxe, a drug development consulting company, helps emerging pharmaceutical and biotechnology companies navigate through all phases of the drug development and commercialization process. TD2, a non-profit Scottsdale subsidiary of the Phoenix-based Translational Genomic Research Institute (TGen), specializes in guiding drug companies through the complexities of setting up and conducting clinical trials, and moving promising drug candidates through the federal review process of the U.S. food and Drug Administration.
"We are excited to work with Rondaxe, since effective CMC management is key to the successful application and approval processes of the FDA, and moving new anti-cancer treatments to market where they can provide patient benefit," said Dr. Stephen Gately, President and Chief Science Officer at TD2.
Jeffrey M. Evans, Ph.D., co-founder and managing partner of Rondaxe, said, "Our clients will benefit measurably from the 'TD2 Solution' by receiving clear clinical and regulatory development path guidance and service support."
The TD2-Rondaxe alliance is designed to bridge a critical gap between chemistry and translational medicine. This blend of expertise will speed research discoveries through the regulatory process to bring new compounds to patients in a risk-reduced and cost-effective manner. TD2 and Rondaxe teams will focus on maximizing their clients' value proposition throughout the early stages of drug-development.
Rondaxe will provide drug development and manufacturing strategies with expertise in chemical, fermentation, drug product and analytical development, supply chain strategy, manufacturing operations, quality control, and quality assurance. TD2 offers an integrated suite of tools that includes preclinical support, clinical trials and regulatory affairs.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Soft millirobots for minimally invasive surgery and drug delivery?

Nanoscale Velcro used for Molecule Transport
Johns Hopkins epilepsy study is first ResearchKit App to use Apple Watch

Pathogenic microbes in drying soils could present public health threat - “A Change is Gonna Come”

How chemicals in plastic may cause lower IQ levels - The effects of environmental chemicals at the molecular level
New genetic marker makes fruit fly a better model for the study of neuronal development and human brain disorders
